Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02559817

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation — LIN-MD-63  

Irritable Bowel Syndrome With Constipation Clinical Trial

Official title:
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 6 to 17 Years, A Multicenter, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (IBS-C) (ie, Fulfill Rome III Criteria for Child/Adolescent IBS and Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of Irritable Bowel syndrome with Constipation (IBS-C), in children age 7-17 years. This study includes up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Patients age 7-11 will receive oral liquid or oral solid capsule and patients 12-17 will receive solid oral capsule formulation. Children ages 7-11 years meeting the entry criteria will be randomized to 1 of 3 doses of linaclotide or placebo for 4 weeks. Children ages 12-17 years meeting the entry criteria will be randomized to 1 of 4 doses of linaclotide or placebo for 4 weeks. This 4-week study will assess the effects of linaclotide on bowel movement frequency, as well as other bowel symptoms of IBS-C.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02559817
Study type Interventional
Source Forest Laboratories
Contact
Status Terminated
Phase Phase 2
Start date November 1, 2015
Completion date August 30, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT00730171 - An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT00215566 - A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c Phase 2
Completed NCT00765999 - An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT02559206 - Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Phase 2
Recruiting NCT05646186 - Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome N/A
Active, not recruiting NCT04026113 - Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) Phase 3
Recruiting NCT05519683 - Home Transcutaneous Electrical Acustimulation (TEA) Phase 2/Phase 3
Enrolling by invitation NCT04166058 - Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C Phase 3
Completed NCT04968652 - IBS-C Questionnaire Study
Completed NCT05164861 - Safety and Efficacy of Non-alcoholic Beverage Based on Kombucha in Patients With Constipations N/A
Completed NCT02590432 - An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Phase 4
Completed NCT00380250 - Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT04647045 - An Evaluation of Cultured Milk Drink on Immune Status of Patients With Irritable Bowel Syndrome: Constipation Predominant N/A
Completed NCT03054506 - The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation N/A
Recruiting NCT04214470 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
Not yet recruiting NCT06219707 - Electro-acupuncture for Irritable Bowel Syndrome With Constipation N/A
Recruiting NCT03596905 - Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) Phase 2
Completed NCT04132804 - Effect of Tai Chi as Treatment for IBS-C N/A
Completed NCT00938717 - Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Phase 3
Completed NCT04997057 - A Multistrain Probiotic in Patients With Irritable Bowel Syndrome With Predominant Constipation N/A